Eickstaedt Joshua B, Starke Samuel, Krakora Dan, Hinshaw Molly, Arkin Lisa M
Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Pediatr Dermatol. 2020 Nov;37(6):1176-1178. doi: 10.1111/pde.14311. Epub 2020 Aug 31.
Actinic prurigo is a rare, idiopathic chronic photodermatosis of childhood characterized by excoriated papules, nodules, and plaques in sun-exposed areas. It is notoriously difficult to treat. The disorder involves a type IV hypersensitivity reaction driven by both Th1 and Th2 inflammatory pathways, the latter of which leads to secretion of IL-4, IL-5, IL-13, and production of B cells, IgE, and IgG4. Dupilumab, an IL-4 receptor antagonist, disrupts the Th2 pathway. We present a pediatric patient with severe, recalcitrant actinic prurigo who achieved rapid and sustained clearance with dupilumab.
光化性痒疹是一种罕见的儿童特发性慢性光皮肤病，其特征为在暴露于阳光的部位出现抓痕性丘疹、结节和斑块。其治疗难度众所周知。该疾病涉及由Th1和Th2炎症途径驱动的IV型超敏反应，后者导致IL-4、IL-5、IL-13的分泌以及B细胞、IgE和IgG4的产生。度普利尤单抗是一种IL-4受体拮抗剂，可阻断Th2途径。我们报告了一名患有严重顽固性光化性痒疹的儿科患者，使用度普利尤单抗后迅速且持续地清除了症状。
